| Previous Close | 93.91 |
| Open | 94.34 |
| Bid | 94.57 x 4000 |
| Ask | 94.58 x 900 |
| Day's Range | 94.39 - 94.77 |
| 52 Week Range | 77.04 - 98.52 |
| Volume | 961,837 |
| Avg. Volume | 1,860,495 |
| Market Cap | 212.411B |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | 27.19 |
| EPS (TTM) | 3.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.20 (3.41%) |
| Ex-Dividend Date | Mar. 04, 2021 |
| 1y Target Est | 105.13 |
- Editor's PickYahoo Finance Video
FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO
Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.
- Zacks
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
- GlobeNewswire
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
First-in-class, oral, targeted factor B inhibitor iptacopan substantially reduced both intra- and extravascular hemolysis when given as monotherapy in a Phase II study of anti-C5 naïve paroxysmal nocturnal hemoglobinuria (PNH) patients1New results are promising for potential use of iptacopan as monotherapy in PNH, a rare and life-threatening blood disorder2,3; results from a previous Phase II study showed iptacopan substantially improved hematological response as add-on to standard-of-care (ecul
